Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
Huangqi Guizhi Wuwu decoction
The First People's Hospital of Lianyungang
Diabetic Nephropathies
1 trial -
Human umbilical cord mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
Hydrochloride anlotinib
Zhongnan Hospital
Uterine Cervical Neoplasms
1 trial -
Hydromorphone combined with ropivacaine
Second Hospital of Jilin University
Inguinal Hernia
1 trial -
Hydroxychloroquine Sulfate 200 MG [Plaquenil]
BRIGHT MINDS BIOSCIENCES INC.
Coronavirus Infection
1 trial -
Hydroxyurea
United Therapeutics Europe Ltd
Thrombocythemia
1 trial -
Hypofractionated Radiation Therapy
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
IMIQUIMOD cream 50mg/g
BRIGHT MINDS BIOSCIENCES INC.
Cutaneous Lupus Erythematosus
1 trial -
Ibuprofen
United Therapeutics Europe Ltd
Immune System and Related Disorders
1 trial -
Immune-enhancing nutritional beverage
United Therapeutics Europe Ltd
Mitigation of Immune Function Decrements in Response to Stress
1 trial -
Indomethacin and Ibuprofen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ductus Arteriosus, Patent
1 trial -
Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
The First People's Hospital of Lianyungang
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
Hospital Authority, Hong Kong
CD30+ Peripheral T-cell Lymphoma
1 trial -
Induction therapy-Pro regimen
The First People's Hospital of Lianyungang
Diffuse Large B-Cell Lymphoma
1 trial -
Infrared thermography
The First People's Hospital of Lianyungang
Chronic Obstructive Pulmonary Disease
1 trial -
Inhaled Placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventilator-Associated Pneumonia (VAP)
1 trial -
Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Second Affiliated Hospital, School of Medicine, Zhejiang University
Asthma
1 trial -
Insulin
United Therapeutics Europe Ltd
Burns
1 trial -
Insulin
The First People's Hospital of Lianyungang
Gestational Diabetes
1 trial -
Insulin Aspart Injection๏ผUBLINยฎ๏ผ
United Therapeutics Europe Ltd
Pharmacokinetics and Pharmacodynamics
1 trial -
Intensive BP control
Chinese University of Hong Kong
Primary Hypertension
1 trial -
Intensive BP treatment group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Interleukin-2
The First People's Hospital of Lianyungang
Beta Thalassemia Major
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources